<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00963417</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000637437</org_study_id>
    <secondary_id>IBCSG-25A-02</secondary_id>
    <secondary_id>BIG-25A-02</secondary_id>
    <secondary_id>NABCI-IBCSG-25A-02</secondary_id>
    <nct_id>NCT00963417</nct_id>
  </id_info>
  <brief_title>Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02</brief_title>
  <acronym>TEXT-Bone</acronym>
  <official_title>TEXT-Bone: A Substudy of the TEXT Trial to Evaluate Serial Bone Markers for Bone Remodeling, Serial Growth Factors, and Bone Mineral Density</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Breast International Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International Breast Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Gathering information over time from bone density and laboratory tests of women
      with breast cancer treated with triptorelin and tamoxifen or exemestane may help the study of
      breast cancer in the future.

      PURPOSE: This clinical trial is studying changes in bone mineral density in women with breast
      cancer treated with triptorelin and tamoxifen or exemestane on protocol IBC SG-25-02 (TEXT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Evaluate changes in bone mineral density (BMD) among premenopausal women randomized in
           protocol IBC SG-25202 (TEXT-2) to receive either: A) triptorelin (GnRH analogue) for 5
           years plus tamoxifen for 5 years; or B) triptorelin (GnRH analogue) for 5 years plus the
           steroidal aromatase inhibitor exemestane for 5 years.

        -  Evaluate serial serum markers for bone remodeling (C-telopeptide, osteocalcin,
           bone-specific alkaline phosphatase) and investigate their correlation with BMD.

        -  Evaluate the relationship of genetic variants of CYP19A1, ERα, ERß, and IGF 1 with BMD.

        -  Evaluate serial serum growth factors (IGF-1 and IGFBP-3) and investigate whether their
           time course correlates with BMD.

        -  Explore the role of serum IGF-1 and IGFBP-3 as biomarkers of disease outcome
           (disease-free survival). (exploratory)

      OUTLINE: Blood samples are collected at baseline and then periodically for 6 years. Serum
      markers of bone remodeling and serum growth factor levels are measured.

      Bone mineral density in the L1-L4 (postero-anterior) region of the spine and femoral neck of
      the hip is measured by DEXA at baseline and then periodically for 6 years.

      Any surplus serum is stored for use in unspecified future research.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serial serum levels of C-telopeptide, osteocalcin, and bone-specific alkaline phosphatase</measure>
    <time_frame>72 months after rnadomization to TEXT Study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serial serum levels of IGF-1 and IGFBP-3</measure>
    <time_frame>72 months after randomization to TEXT Study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serial BMD measurements of the L1-L4 (postero-anterior, PA) region of the spine and hip by dual-energy X-ray absorptiometry (DEXA)</measure>
    <time_frame>72 months after randomization to TEXT Study</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Triptorelin plus tamoxifen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Determination of bone mineral density in patients randomized in TEXT-1 or TEXT-2 trials to receive triptorelin (GnRH analogue) for 5 years plus tamoxifen for 5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triptorelin plus exemestane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determination of bone mineral density in patients randomized in TEXT-1 or TEXT-2 trials to receive triptorelin (GnRH analogue) for 5 years plus exemestane for 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Serial serum levels of several biomarkers will be analyzed at different time points, up to 72 months after randomization.</description>
    <arm_group_label>Triptorelin plus tamoxifen</arm_group_label>
    <arm_group_label>Triptorelin plus exemestane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>dual x-ray absorptiometry</intervention_name>
    <description>Serial bone mineral density measurements of the L1-L4 (postero-anterior, PA) region of the spine and hip by dual-energy X-ray absorptiometry (DEXA).</description>
    <arm_group_label>Triptorelin plus tamoxifen</arm_group_label>
    <arm_group_label>Triptorelin plus exemestane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Patient must be eligible and enrolled in the TEXT-2 trial prior to enrolling in
             TEXT-Bone

          -  Serial bone marrow density (BMD) measurements must be taken within the same
             institution

          -  Hormone receptor positive

        PATIENT CHARACTERISTICS:

          -  See Disease Characteristics

          -  Premenopausal

          -  No bone fracture in the past 6 months that, in the investigator's judgement, could be
             related to bone fragility

          -  No clinical or biochemical malabsorption syndrome, known vitamin D deficiency, active
             hyper- or hypoparathyroidism, or Paget's disease

          -  No uncontrolled thyroid disease, Cushing disease, or other pituitary diseases

          -  No other bone disease (including osteomalacia or osteogenesis imperfecta)

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 6 months since prior and no concurrent bisphosphonate therapy (or other bone
             therapies such as PTH or strontium)

          -  At least 6 months since prior glucocorticoid (&gt; 5 mg prednisone or equivalent) for &gt; 1
             month

          -  At least 12 months since prior anticonvulsants
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivia Pagani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Center</name>
      <address>
        <city>East Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maroondah Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Huy</name>
      <address>
        <city>Huy</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. Sart Tilman</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.P.L.T. de Verviers</name>
      <address>
        <city>Verviers</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Institute of Southern Switzerland</name>
      <address>
        <city>Bellinzona</city>
        <zip>CH-6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St.Gallen</name>
      <address>
        <city>St.Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2009</study_first_submitted>
  <study_first_submitted_qc>August 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2009</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>estrogen receptor-positive breast cancer</keyword>
  <keyword>progesterone receptor-positive breast cancer</keyword>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

